(Q36223644)

12 August 2017

1 reference

title

Immunotherapy for melanoma: the good, the bad, and the future (English)

1 reference

12 August 2017

1 reference

6

Bernard A Fox

1 reference

12 August 2017

Christian H Poehlein

1

1 reference

12 August 2017

Dominik Rüttinger

2

1 reference

12 August 2017

Jun Ma

3

1 reference

12 August 2017

Hong-Ming Hu

4

1 reference

12 August 2017

Walter J Urba

5

1 reference

12 August 2017

publication date

1 September 2005

1 reference

12 August 2017

published in

Current Oncology Reports

1 reference

12 August 2017

volume

7

1 reference

12 August 2017

issue

5

1 reference

12 August 2017

page(s)

383-392

1 reference

Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11912-005-0066-1

TNF plays an essential role in tumor regression after adoptive transfer of perforin/IFN-gamma double knockout effector T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-005-0066-1

CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-005-0066-1

Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-005-0066-1

Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-005-0066-1

Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2

21 January 2018

1 reference

12 December 2020

Type 1 versus type 2 cytokine release by Vbeta T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role

1 reference

12 December 2020

CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death.

1 reference

12 December 2020

Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma

1 reference

12 December 2020

CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes

1 reference

12 December 2020

Enhanced therapeutic potential of adoptive immunotherapy by in vitro CD28/4-1BB costimulation of tumor-reactive T cells against a poorly immunogenic, major histocompatibility complex class I-negative A9P melanoma

1 reference

12 December 2020

The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation.

1 reference

12 December 2020

Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance

1 reference

12 December 2020

Examining the immune response in sentinel lymph nodes of mice and men

1 reference

12 December 2020

Anti-tumor immunity and autoimmunity: a balancing act of regulatory T cells

1 reference

12 December 2020

Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2

1 reference

12 December 2020

Role of 4-1BB:4-1BB ligand in cancer immunotherapy.

1 reference

12 December 2020

Therapeutic potential of 4-1BB (CD137) as a regulator for effector CD8(+) T cells

1 reference

12 December 2020

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

1 reference

12 December 2020

OX40: targeted immunotherapy--implications for tempering autoimmunity and enhancing vaccines

1 reference

12 December 2020

Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction

1 reference

12 December 2020

Immunopotentiating role of IFN-gamma in early and late stages of type 1 CD8 effector cell-mediated tumor rejection

1 reference

12 December 2020

Revisiting immunosurveillance and immunostimulation: Implications for cancer immunotherapy

1 reference

12 December 2020

Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors

1 reference

12 December 2020

Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma

1 reference

12 December 2020

Anti-tumor T cell response and protective immunity in mice that received sublethal irradiation and immune reconstitution.

1 reference

12 December 2020

Cancer immunotherapy: moving beyond current vaccines

1 reference

12 December 2020

Enhancement of antitumor immunity by CTLA-4 blockade

1 reference

12 December 2020

Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells.

1 reference

12 December 2020

The expanding universe of T-cell subsets: Th1, Th2 and more.

1 reference

12 December 2020

Biochemotherapy for melanoma: rational therapeutics in the search for weapons of melanoma destruction

1 reference

12 December 2020

Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma

1 reference

12 December 2020

Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma

1 reference

12 December 2020

A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma

1 reference

12 December 2020

Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile.

1 reference

12 December 2020

Costimulation of T cells by OX40, 4-1BB, and CD27.

1 reference

12 December 2020

Development of antitumor immune responses in reconstituted lymphopenic hosts.

1 reference

12 December 2020

Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.

1 reference

12 December 2020

Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis

1 reference

12 December 2020

The B7 family revisited

1 reference

12 December 2020

Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases

1 reference

12 December 2020

Adoptive cellular therapy with tumor vaccine draining lymph node lymphocytes after vaccination with HLA-B7/beta2-microglobulin gene-modified autologous tumor cells

1 reference

12 December 2020

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

1 reference

12 December 2020

Human melanoma cells inhibit the earliest differentiation steps of human Langerhans cell precursors but failed to affect the functional maturation of epidermal Langerhans cells

1 reference

12 December 2020

Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma

1 reference

12 December 2020

Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells

1 reference

12 December 2020

Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma

1 reference

12 December 2020

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

1 reference

12 December 2020

Vaccination of women with metastatic breast cancer, using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast cancer cell line: clinical and immunological results

1 reference

12 December 2020

Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer

1 reference

12 December 2020

Regulatory T cells and tumor immunity

1 reference

12 December 2020

Engagement of the OX-40 receptor in vivo enhances antitumor immunity

1 reference

12 December 2020

Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice

1 reference

12 December 2020

Differential expression of transforming growth factor beta 1 and interleukin 10 in progressing and regressing areas of primary melanoma.

1 reference

12 December 2020

TNF/TNFR family members in costimulation of T cell responses

1 reference

12 December 2020

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

1 reference

12 December 2020

Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer

1 reference

12 December 2020

CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression

1 reference

12 December 2020

CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma.

1 reference

12 December 2020

Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer

1 reference

12 December 2020

Manipulating the host response to autologous tumour vaccines.

1 reference

12 December 2020

Increase of regulatory T cells in the peripheral blood of cancer patients.

1 reference

12 December 2020

T Helper 1 Cytokine mRNA Is Increased in Spontaneously Regressing Primary Melanomas

1 reference

12 December 2020

Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma

1 reference

12 December 2020

Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth.

1 reference

12 December 2020

A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma

1 reference

12 December 2020

Tumour-induced polarization of tumour vaccine-draining lymph node T cells to a type 1 cytokine profile predicts inherent strong immunogenicity of the tumour and correlates with therapeutic efficacy in adoptive transfer studies.

1 reference

12 December 2020

Successful treatment of malignant melanoma in situ with topical 5% imiquimod cream

1 reference

12 December 2020

10.1007/S11912-005-0066-1

Identifiers

DOI

1 reference

12 August 2017

1 reference